An Executive Informational Overview (EIO) is now available on Hybrid Software Group PLC, a developer of software and hardware enterprise solutions for industrial inkjet printing. The 80-page report details the Company's business, its strategy, market opportunities, competition, financials, risks, and more. It is available for download below.

Read More
Topics:
hybrid software group,
hysg,
inkjet printing,
enterprise software,
hardware,
global graphics,
color logic,
ic3d,
original equipment manufacturers,
hybrid software
Crystal Research Associates has issued an 18-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Read More
Topics:
immunotherapy,
malaria,
hemorragic fever,
geovax,
vaccines,
cancer,
covid19,
coronovirus,
covid-19,
monkeypox
Crystal Research Associates has issued a 16-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Read More
Topics:
immunotherapy,
malaria,
hemorragic fever,
geovax,
vaccines,
cancer,
covid19,
coronovirus,
covid-19,
monkeypox
An updated Executive Informational Overview (EIO) is now available on CEL-SCI Corporation, a clinical-stage biotechnology company developing immunotherapy technologies to treat cancer, autoimmune, and infectious diseases. The 98-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Read More
Topics:
biotech,
immunotherapy,
CEL-SCI,
infectious diseases,
leaps,
cancer,
autoimmune,
head and neck cancer,
squamous cell carcinoma,
rheumatoid arthritis,
covid19,
cervical dysplasia
An Executive Informational Overview (EIO) is now available on Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies, primarily for rare and orphan diseases, with an initial focus on Sickle Cell Disease (SCD). The 76-page report details the Company's business, its strategy, market opportunities, competition, financials, risks, and more. It is available for download below.

Read More
Topics:
orphan diseases,
EMMA,
orphan drug,
sickle cell crisis,
The Steve Harvey Show,
emmaus life sciences,
sickle cell disease,
L-glutamine,
endari,
diverticulosis
A 13-page Quarterly Update is now available on Bioxytran, Inc., a clinical stage pharmaceutical company developing therapeutics in two areas: (1) glycovirology and anti-viral therapeutics; and (2) hypoxic conditions, necrosis, and degenerative diseases.
Read More
Topics:
covid19,
coronovirus,
SARS-CoV-2,
galectrin-3,
glycovirology,
bioxytran,
complex carbohydrate chemistry,
galectin
Crystal Research Associates has issued a 17-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Read More
Topics:
immunotherapy,
malaria,
hemorragic fever,
geovax,
vaccines,
cancer,
covid19,
coronovirus,
covid-19,
monkeypox
An Executive Informational Overview (EIO) is now available on SG Blocks, Inc., a leading developer, designer, and fabricator of modular structures, meeting the growing demand for safe and green construction. The 64-page report details the Company's business, its strategy, market opportunities, competition, financials, risks, and more. It is available for download below.

Read More
Topics:
SG Blocks,
modular construction,
green building,
COVID-19 testing,
Starbucks,
Taco Bell,
Sanitec,
green construction,
shipping containers,
GreenSteel,
cargo modified modules,
Verizon,
Puma,
Lacoste,
NBA,
Equinox,
Clarity Lab Solutions,
SGBX
An Executive Informational Overview (EIO) is now available on Bioxytran, Inc., a clinical stage pharmaceutical company developing therapeutics in two areas: (1) glycovirology and anti-viral therapeutics; and (2) hypoxic conditions, necrosis, and degenerative diseases. The 70-page report details the Company's business, its strategy, market opportunities, competition, financials, risks, and more. It is available for download below.

Read More
Topics:
covid19,
coronovirus,
SARS-CoV-2,
galectrin-3,
glycovirology,
bioxytran,
complex carbohydrate chemistry,
galectin
Crystal Research Associates has issued a 19-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Read More
Topics:
immunotherapy,
malaria,
hemorragic fever,
geovax,
vaccines,
cancer,
covid19,
coronovirus,
covid-19,
monkeypox
An Executive Informational Overview (EIO) is now available on Genprex, Inc., a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The 62-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Read More
Topics:
cancer,
REQORSA,
genprex,
diabetes,
gene therapy,
non-small cell lung cancer,
small-cell lung cancer
An Executive Informational Overview (EIO) is now available on ImmunoPrecise Antibodies Ltd, a full-service contract research organization (CRO) for therapeutic antibody discovery and development. The 72-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Read More
Topics:
biotech,
biopharmaceuticals,
biotechnology,
Oncology,
Biologics,
Humanized monoclonal antibodies,
Immunoassay,
Immunogen,
Monoclonal antibody,
Antibody,
Contract research organization (CRO),
Customer relationship management (CRM),
Human monoclonal antibodies,
SARS-CoV-2,
Polyclonal antibody,
Contract manufacturing organization (CMO),
Enterprise resource planning (ERP)
Crystal Research Associates has issued a 15-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Read More
Topics:
immunotherapy,
malaria,
hemorragic fever,
geovax,
vaccines,
cancer,
covid19,
coronovirus,
covid-19
Crystal Research Associates has issued a 15-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Read More
Topics:
immunotherapy,
malaria,
hemorragic fever,
geovax,
vaccines,
cancer,
covid19,
coronovirus,
covid-19
An Executive Informational Overview (EIO) is now available on FSD Pharma Inc., a biopharmaceutical company focused on developing innovative therapies for brain and inflammatory disorders to improve patient quality of life. The 58-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Read More
Topics:
biotech,
biopharmaceuticals,
biotechnology,
neurodegenerative,
multiple sclerosis,
inflammatory,
MS,
major depressive disorder (MDD),
myelin degradation,
bipilar disorder